Table 1.
Baseline characteristics in the intention-to-treat population
| Molnupiravir (n=90) | Placebo (n=90) | Total (n=180) | ||
|---|---|---|---|---|
| Demographics | ||||
| Age at consent, years | 45 (31–55) | 43 (28–54) | 43 (28–55) | |
| Sex | ||||
| Female | 52 (58%) | 51 (57%) | 103 (57%) | |
| Male | 38 (42%) | 39 (43%) | 77 (43%) | |
| Ethnicity | ||||
| White English, Welsh, Scottish, Northern Irish, or British | 73 (81%) | 78 (87%) | 151 (84%) | |
| Any other White background | 13 (14%) | 7 (8%) | 20 (11%) | |
| Asian or British Asian: Indian | 1 (1%) | 1 (1%) | 2 (1%) | |
| Mixed or part of multiple ethnic groups: White and Black African | 1 (1%) | 0 | 1 (1%) | |
| Mixed or part of multiple ethnic groups: White and Asian | 0 | 1 (1%) | 1 (1%) | |
| Black, African, Caribbean, or Black British–Caribbean | 1 (1%) | 0 | 1 (1%) | |
| Asian or British Asian: Pakistani | 0 | 1 (1%) | 1 (1%) | |
| Asian or British Asian: Chinese | 0 | 1 (1%) | 1 (1%) | |
| Any other Black, African, or Caribbean background | 1 (1%) | 0 | 1 (1%) | |
| Any other Asian background | 0 | 1 (1%) | 1 (1%) | |
| Body-mass index, kg/m2 | 28·2 (24·2–32·2) | 27·1 (23·6–31·6) | 27·4 (24·0–32·0) | |
| Disease characteristics | ||||
| Time from symptom onset to randomisation, days | 3·5 (3·0–4·0) | 3·0 (3·0–4·0) | 3·0 (3·0–4·0) | |
| National Early Warning Score 2 | 0·3 (0·6) | 0·4 (0·8) | 0·3 (0·7) | |
| SARS-CoV-2 variant | ||||
| Alpha (B.1.1.7) | 17 (19%) | 20 (22%) | 37 (21%) | |
| B.1.1.1 | 0 | 1 (1%) | 1 (1%) | |
| EU1 (B.1.177) | 15 (17%) | 13 (14%) | 28 (16%) | |
| Omicron (B.1.1.529) BA.1 | 15 (17%) | 12 (13%) | 27 (15%) | |
| Omicron (B.1.1.529) BA.2 | 5 (6%) | 6 (7%) | 11 (6%) | |
| Delta (B.1.617.2) | 37 (41%) | 35 (39%) | 72 (40%) | |
| XE | 0 | 1 (1%) | 1 (1%) | |
| Unknown | 1 (1%) | 2 (2%) | 3 (2%) | |
| Viral load | ||||
| n | 89 | 89 | 178 | |
| Mean, log10copies per reaction | 7·1 (2·7) | 7·4 (3·0) | 7·2 (2·9) | |
| Vaccinated against COVID-19* | ||||
| No | 46 (51%) | 44 (49%) | 90 (50%) | |
| Yes | 44 (49%) | 46 (51%) | 90 (50%) | |
| First vaccine received | ||||
| Pfizer–BioNTech (BNT162b2) | 21/44 (48%) | 26/46 (57%) | 47/90 (52%) | |
| AstraZeneca (ChAdOx1 nCoV-19) | 21/44 (48%) | 17/46 (37%) | 38/90 (42%) | |
| Novavax (NVX-CoV2373) | 1/44 (2%) | 0 | 1/90 (1%) | |
| Unknown | 1/44 (2%) | 3/46 (7%) | 4/90 (4%) | |
| Second vaccine received | ||||
| Pfizer–BioNTech (BNT162b2) | 15/35 (43%) | 22/34 (65%) | 37/69 (54%) | |
| AstraZeneca (ChAdOx1 nCoV-19) | 17/35 (49%) | 11/34 (32%) | 28/69 (41%) | |
| Novavax (NVX-CoV2373) | 1/35 (3%) | 0 | 1/69 (1%) | |
| Unknown | 2/35 (6%) | 1/34 (3%) | 3/69 (4%) | |
| Third vaccine received | ||||
| Pfizer–BioNTech (BNT162b2) | 12/12 (100%) | 6/7 (86%) | 18/19 (95%) | |
| Moderna (mRNA-1273) | 0 | 1/7 (14%) | 1/19 (5%) | |
Data are median (IQR), n (%), mean (SD), or n/N, unless otherwise specified.
*
A patient was deemed vaccinated if they had received at least one COVID-19 vaccine at least 14 days before entry into the trial.